Opsens Inc.

Opsens Inc.

OPSSF

OPSSFOpsens Inc. US flag

Other OTC

2.14

USD

+0.01

- -

247.43MMarket Cap

Opsens Inc.

OPSSF

(Other OTC)

Recent

price

2.14

P/E

ratio

- -

div

yld

- -

ROIC.AI

No data availableFinancial data will appear here once available

Capital Structure

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Quarterly Revenue

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Similar Companies: Alcon Inc. (0A0D.L)
Gerresheimer AG (GXI.DE)
Yubo International Biotech Limited (YBGJ)
Sincere Co., Ltd. (7782.T)
Becton, Dickinson and Company (BDXB)
Tristel PLC (TSTL.L)
Business: Opsens Inc. (OTCQX: OPSSF; TSX: OPS) develops, manufactures, and commercializes innovative medical devices focused on guidewires and optical sensors for minimally invasive cardiovascular procedures, including fractional flow reserve (FFR) and instantaneous wave-free ratio (iFR) measurements; the company offers products such as the OptoWire and OptoProbes for pressure and temperature sensing, MicroWire for coronary physiology, SavvyWire for transcatheter aortic valve replacement (TAVR) guidance, and related consoles and software platforms. Founded in 2007 and headquartered in Quebec City, Canada, Opsens operates primarily in North America and Europe, serving interventional cardiologists and hospitals through direct sales and distribution partners in the cardiovascular medical device segment. The company targets acute and chronic coronary artery disease markets, providing fiber optic-based sensors that deliver high-fidelity hemodynamic data with reduced signal drift compared to traditional pressure wires. In recent developments, Opsens secured FDA clearance for its SavvyWire Leader in June 2024, expanding its TAVR portfolio; the company also completed a strategic financing round in late 2023 to support U.S. market penetration and reported positive clinical results from the SAFE-TAVI trial demonstrating SavvyWire's procedural efficiencies. Additionally, Opsens announced a distribution agreement with MedAlliance in 2024 to broaden access to its FFR products in select European regions and underwent a ticker symbol change on the TSX to reflect its growing U.S. presence.

Company News